Literature DB >> 19556880

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.

Elena V Kurenova1, Darrell L Hunt, Dihua He, Ann D Fu, Nicole A Massoll, Vita M Golubovskaya, Christopher A Garces, William G Cance.   

Abstract

Vascular endothelial growth factor receptor-3 is a receptor tyrosine kinase that is overexpressed in some human carcinomas, but its role in tumorigenesis has not been fully elucidated. We examined VEGFR-3 expression in normal, nonneoplastic and early stage malignant breast tissues and have shown that VEGFR-3 upregulation in breast cancer preceded tumor cell invasion, suggesting that VEGFR-3 may function as a survival signal. We characterized the biological effects of VEGFR-3 over-expression in human breast cancer cells based on two approaches: gain of function by overexpressing VEGFR-3 in MCF-7 breast cancer cells and loss of function by RNAi-mediated silencing of VEGFR-3 in MCF-7-VEGFR-3 and BT474 cells. VEGFR-3 overexpression increased cellular proliferation by 40% when MCF7-VEGFR-3 cells were compared to parental MCF7 cells, and proliferation was reduced by more than 40% when endogenous VEGFR-3 was downregulated in BT474 cells. VEGFR-3 overexpression promoted a three-fold increase in motility and invasion and both motility and invasion were inhibited by downregulation of VEGFR-3. Furthermore, VEGFR-3 overexpression promoted cellular survival under stress conditions induced by staurosporine treatment and led to anchorage-independent growth. VEGFR-3 overexpression dramatically increased tumor formation in both hormone-dependent and independent xenograft models. With estrogen stimulation, MCF7-VEGFR-3 xenografts were ten times larger than control xenografts. Finally, downregulation of VEGFR-3 expression in both xenograft model cell lines led to a significant reduction of tumor growth. For the first time, we have demonstrated that VEGFR-3 overexpression promotes breast cancer cell proliferation, motility, survival, anchorage-independent growth and tumorogenicity in the absence of ligand expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556880      PMCID: PMC3619978          DOI: 10.4161/cc.8.14.9101

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

1.  Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice.

Authors:  Y Yanai; T Furuhata; Y Kimura; K Yamaguchi; T Yasoshima; T Mitaka; Y Mochizuki; K Hirata
Journal:  J Exp Clin Cancer Res       Date:  2001-09

2.  Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma.

Authors:  A Kabashima; Y Maehara; Y Kakeji; K Sugimachi
Journal:  Oncology       Date:  2001       Impact factor: 2.935

3.  Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer.

Authors:  Y Yonemura; S Fushida; E Bando; K Kinoshita; K Miwa; Y Endo; K Sugiyama; T Partanen; H Yamamoto; T Sasaki
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

4.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer.

Authors:  Masayo Kawakami; Tomohisa Furuhata; Yasutoshi Kimura; Koji Yamaguchi; Fumitake Hata; Kazuaki Sasaki; Koichi Hirata
Journal:  Surgery       Date:  2003-03       Impact factor: 3.982

6.  VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.

Authors:  Mirjami M-T Mattila; Johanna K Ruohola; Terhi Karpanen; David G Jackson; Kari Alitalo; Pirkko L Härkönen
Journal:  Int J Cancer       Date:  2002-04-20       Impact factor: 7.396

7.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.

Authors:  M Skobe; T Hawighorst; D G Jackson; R Prevo; L Janes; P Velasco; L Riccardi; K Alitalo; K Claffey; M Detmar
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

8.  Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

Authors:  T Karpanen; M Egeblad; M J Karkkainen; H Kubo; S Ylä-Herttuala; M Jäättelä; K Alitalo
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

9.  Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma.

Authors:  Deborah Witte; Abraham Thomas; Najeeba Ali; Nicole Carlson; Mamoun Younes
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

10.  Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.

Authors:  Y Yokoyama; D S Charnock-Jones; D Licence; A Yanaihara; J M Hastings; C M Holland; M Emoto; M Umemoto; T Sakamoto; S Sato; H Mizunuma; S K Smith
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  19 in total

1.  Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.

Authors:  Priyanka N Gogate; Elena V Kurenova; Manivannan Ethirajan; Jianqun Liao; Michael Yemma; Arindam Sen; Ravindra K Pandey; William G Cance
Journal:  Cancer Lett       Date:  2014-07-24       Impact factor: 8.679

2.  VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner.

Authors:  Michelle L Varney; Rakesh K Singh
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.

Authors:  Xue-Feng Ni; Chang-Ping Wu; Jing-Ting Jiang
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

5.  Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.

Authors:  Priyanka N Gogate; Manivannan Ethirajan; Elena V Kurenova; Andrew T Magis; Ravindra K Pandey; William G Cance
Journal:  Eur J Med Chem       Date:  2014-04-15       Impact factor: 6.514

6.  VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.

Authors:  Seiji Shigetomi; Yorihisa Imanishi; Katsushi Shibata; Nobuya Sakai; Koji Sakamoto; Ryoichi Fujii; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Yoshihiro Watanabe; Masayuki Shimoda; Kaori Kameyama; Hiroyuki Ozawa; Toshiki Tomita; Kaoru Ogawa
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

7.  Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism.

Authors:  Yanling Chen; Lei Jiang; Feifei She; Nanhong Tang; Xiaoqian Wang; Xiujin Li; Shenghua Han; Jinhai Zhu
Journal:  Mol Cell Biochem       Date:  2010-08-25       Impact factor: 3.396

8.  An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.

Authors:  Yan Chen; Xin Liu; Cong Guo Jin; Yong Chun Zhou; Roya Navab; Kristine Raaby Jakobsen; Xiao Qun Chen; Jia Li; Ting Ting Li; Lu Luo; Xi Cai Wang
Journal:  Tumour Biol       Date:  2015-09-16

9.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

10.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Authors:  Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle
Journal:  Mol Carcinog       Date:  2013-07-19       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.